NCT00398450 2021-03-03
Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma
University of California, San Diego
Phase 1 Completed
Clinical Trials
10 trialsNCT02339324 2021-02-24
Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
University of Pittsburgh
Phase 1 Completed
NCT00498979 2020-07-24
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Case Comprehensive Cancer Center
Phase 1 Completed
NCT01603212 2019-05-21
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00629200 2018-11-15
Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00311558 2018-01-26
Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma
The Cleveland Clinic
Phase 1 Terminated
NCT01622933 2017-08-31
Multiple Antigen-Engineered DC Vaccine for Melanoma
University of Pittsburgh
Phase 1 Completed
NCT01409174 2017-05-31
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00217542 2013-05-03
Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT00970996 2013-01-03
BCAA
M.D. Anderson Cancer Center
Phase 1 Completed